kaletra- lopinavir and ritonavir tablet, film coated
remedyrepack inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see microbiology ( 12.4)] . - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - kaletra is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions ( 7.1) and clinical pharmacology ( 12.3)] . alpha 1- adr
norvir- ritonavir tablet, film coated norvir- ritonavir solution norvir- ritonavir powder
abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ritonavir 100 mg - norvir tablets and oral solution are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. norvir oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with hiv-1 infection. - when co-administering norvir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. - norvir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. - norvir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions ( 7.1 ) and clinical pharmacology ( 12.3 )] . ○ alpha 1- adrenoreceptor antagonist : alfuzosin ○ antianginal: ranolazine ○ antiarrhythmics: amiodarone, dronedarone, flecainide, propaf
technivie- ombitasvir and paritaprevir and ritonavir kit
abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86) - ritonavir 50 mg - technivie is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis or with compensated cirrhosis [see clinical studies (14)] . - the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - technivie is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmacology (12.3)] : alpha1-adrenoreceptor antagonist: alfuzosin hcl anti-anginal: ranolazine antiarrhythmic: dronedarone anti-gout: colchicine in patients with renal and/or hepat
viekira xr- dasabuvir and ombitasvir and paritaprevir and ritonavir kit
abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), dasabuvir sodium monohydrate (unii: og6d40m62l) (dasabuvir - unii:de54eqw8t1), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8) - ritonavir 33.33 mg - viekira xr is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1b infection without cirrhosis or with compensated cirrhosis - genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira xr is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira xr is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmac
norvir ritonavir 600mg/7.5ml oral liquid bottle
abbvie pty ltd - ritonavir -
kaletra- lopinavir and ritonavir tablet, film coated
dispensing solutions, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. - co-administration of kaletra is contraindicated with drugs tha
lopinavir/ritonavir accord 200 mg - 50 mg film-coat. tabl.
accord healthcare b.v. - lopinavir 200 mg; ritonavir 50 mg - film-coated tablet - 200 mg - 50 mg - lopinavir 200 mg; ritonavir 50 mg - lopinavir and ritonavir
lopinavir 100mg and ritonavir 25 mg tablets film-coated tablet
lopinavir and ritonavir - film-coated tablet - lopinavir 100mg and ritonavir 25 mg tablets - ritonavir
lopinavir 200mg & ritonavir 50mg tablets
aurobindo pharma limited unit iii, survey no. 313, bachupally village, - lopinavir & ritonavir tablets. - tablet - lopinavir 200mg & ritonavir 50mg tablets. - antivirals for systemic use:
aluvia 100/25
abbvie (pty) ltd - lopinavir, ritonavir - tablet - each film-coated tablet contains lopinavir 100,0 mg , ritonavir 25,0 mg